RT Book, Section
A1 Slusher, Tina M.
A1 Olusanya, Bolajoko O.
A2 Stevenson, David K.
A2 Maisels, M. Jeffrey
A2 Watchko, Jon F.
SR Print(0)
ID 56324207
T1 Chapter 13. Neonatal Jaundice in Low- and Middle-Income Countries
T2 Care of the Jaundiced Neonate
YR 2012
FD 2012
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-176289-2
LK accesspediatrics.mhmedical.com/content.aspx?aid=56324207
RD 2024/04/18
AB For  the  most  part,  in  the  developed  world,  neonatal  jaundice  occurs  without  significant  morbidity  and/or  mortality  due  to  early  diagnosis  and  treatment.1  However,  most  literature  from  low-middle-income  countries  (LMICs)  suggests  that  it  accounts  for  significant  morbidity  and  mortality  in  contrast  to  that  in  the  United  States  and  developed  world  (Table  13-1).2–18  For  example,  based  on  limited  population-based  data  available  worldwide,  severe  neonatal  jaundice  is  about  100-fold  greater  in  Nigeria  than  in  the  developed  world.  In  one  of  the  few  population-based  studies  from  the  developed  world,  Ebbesen  et  al.17  from  Denmark  reported  that  24/100,000  neonates  met  exchange  blood  transfusion  (exchange  transfusion  [ET])  criteria,  while  9/100,000  developed  acute  bilirubin  encephalopathy  (ABE),  in  comparison  to  results  from  the  only  population-based  study  in  Nigeria,  in  which  Olusanya  et  al.  reported  1860/100,000  infants  had  an  EBT.19  Based  on  the  limited  data  available,  ABE  is  at  least  as  common  as  tetanus  as  a  cause  of  neonatal  deaths  in  Nigeria,  Kenya,  and  Pakistan,11,13,20–23  and  likely  in  most  LMICs  often  ranking  as  one  of  the  top  five  causes  of  neonatal  death.8,11,13,24